A systems biology view of blood vessel growth and remodelling

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 8, 2014, Pages 1491-1508

  Logsdon, Elizabeth A ^a   Finley, Stacey D ^b   Popel, Aleksander S ^b   MacGabhann, Feilim ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Computational model; Mathematical model; Multi scale modelling; Systems biology

Indexed keywords

ANGIOGENESIS; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; HUMAN; SYSTEMS BIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; SYSTEMS BIOLOGY;

EID: 84912572768     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12164     Document Type: Article

References (219)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932-6.
2. Sung H-K, Michael IP, Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr Opin Hematol. 2010; 17: 206-12.
3. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Arch. 2009; 457: 963-77.
4. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653-60.
5. Bentley K, Jones M, Cruys B. Predicting the future: towards symbiotic computational and experimental angiogenesis research. Exp Cell Res. 2013; 319: 1240-6.
6. Skalak TC. Angiogenesis and microvascular remodeling: a brief history and future roadmap. Microcirculation. 2005; 12: 47-58.
7. Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008; 451: 1008-12.
8. Fraisl P, Mazzone M, Schmidt T, et al. Regulation of angiogenesis by oxygen and metabolism. Dev Cell. 2009; 16: 167-79.
9. Song JW, Munn LL. Fluid forces control endothelial sprouting. Proc Natl Acad Sci USA. 2011; 108: 15342-7.
10. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev. 1992; 72: 369-417.
11. Hudlicka O, Brown MD. Adaptation of skeletal muscle microvasculature to increased or decreased blood flow: role of shear stress, nitric oxide and vascular endothelial growth factor. J Vasc Res. 2009; 46: 504-12.
12. Brown MD, Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: involvement of VEGF and metalloproteinases. Angiogenesis. 2003; 6: 1-14.
13. Clark ER. Studies on the growth of bloodvessels in the tail of the frog larva: by observation and experiment on the living animal. Am J Anat. 1918; 23: 37-88.
14. Thoma R. Ueber die abhangigkeit der Bindegewehsneubildung in der Arterieintima von der mechanischen Bedingungen des Blutumlaufes. Arch Pathol Anat Physiol Klin Med. 1883; 93: 433-505.
15. Krogh A. The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol. 1919; 52: 409-15.
16. Pries AR, Reglin B, Secomb TW. Modeling of angioadaptation: insights for vascular development. Int J Dev Biol. 2011; 55: 399-405.
17. Pries AR, Secomb TW. Modeling structural adaptation of microcirculation. Microcirculation. 2008; 15: 753-64.
18. Pries AR, Reglin B, Secomb TW. Remodeling of blood vessels: responses of diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension. 2005; 46: 725-31.
19. Pries AR, Secomb TW, Gaehtgens P. Structural adaptation and stability of microvascular networks: theory and simulations. Am J Physiol. 1998; 275: H349-60.
20. Reglin B, Secomb TW, Pries AR. Structural adaptation of microvessel diameters in response to metabolic stimuli: where are the oxygen sensors? Am J Physiol Heart Circ Physiol. 2009; 297: H2206-19.
21. Ji JW, Tsoukias NM, Goldman D, et al. A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. J Theor Biol. 2006; 241: 94-108.
22. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005; 63: 25-36.
23. Lamkin-Kennard KA, Buerk DG, Jaron D. Interactions between NO and O2 in the microcirculation: a mathematical analysis. Microvasc Res. 2004; 68: 38-50.
24. Godde R, Kurz H. Structural and biophysical simulation of angiogenesis and vascular remodeling. Dev Dyn. 2001; 220: 387-401.
25. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006; 6: 521-34.
26. Goldman D. Theoretical models of microvascular oxygen transport to tissue. Microcirculation. 2008; 15: 795-811.
27. Toma-Dasu I, Dasu A. Modelling tumour oxygenation, reoxygenation and implications on treatment outcome. Comput Math Methods Med. 2013; 2013: 141087.
28. Kavdia M. Mathematical and computational models of oxidative and nitrosative stress. Crit Rev Biomed Eng. 2011; 39: 461-72.
29. Liu G, Mac Gabhann F, Popel AS. Effects of fiber type and size on the heterogeneity of oxygen distribution in exercising skeletal muscle. PLoS ONE. 2012; 7: e44375.
30. Laise P, Di Patti F, Fanelli D, et al. Deterministic and stochastic aspects of VEGF-A production and the cooperative behavior of tumoral cell colony. J Theor Biol. 2011; 272: 55-63.
31. Qutub AA, Popel AS. A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. J Cell Sci. 2006; 119: 3467-80.
32. Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 1-18.
33. Balding D, McElwain DL. A mathematical model of tumour-induced capillary growth. J Theor Biol. 1985; 114: 53-73.
34. Anderson AR, Chaplain MA. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol. 1998; 60: 857-99.
35. Macklin P, McDougall S, Anderson AR, et al. Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol. 2009; 58: 765-98.
36. Shirinifard A, Gens JS, Zaitlen BL, et al. 3D multi-cell simulation of tumor growth and angiogenesis. PLoS ONE. 2009; 4: e7190.
37. Frieboes HB, Jin F, Chuang YL, et al. Three-dimensional multispecies nonlinear tumor growth-II: tumor invasion and angiogenesis. J Theor Biol. 2010; 264: 1254-78.
38. Andasari V, Roper RT, Swat MH, et al. Integrating intracellular dynamics using CompuCell 3D and Bionetsolver: applications to multiscale modelling of cancer cell growth and invasion. PLoS ONE. 2012; 7: e33726.
39. McDougall SR, Anderson AR, Chaplain MA. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol. 2006; 241: 564-89.
40. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91: 1071-121.
41. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012; 2: a006486.
42. Stefanini MO, Qutub AA, Mac Gabhann F, et al. Computational models of VEGF-associated angiogenic processes in cancer. Math Med Biol. 2012; 29: 85-94.
43. Chaplain MA, McDougall SR, Anderson AR. Mathematical modeling of tumorinduced angiogenesis. Annu Rev Biomed Eng. 2006; 8: 233-57.
44. Jackson TL. Modeling tumor vasculature: molecular, cellular, and tissue level aspects and implications. New York, NY: Springer; 2012.
45. Kim E, Stamatelos S, Cebulla J, et al. Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng. 2012; 40: 2425-41.
46. Laurent J, Touvrey C, Botta F, et al. Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol. 2011; 55: 527-34.
47. Pettet GJ, Byrne HM, McElwain DL, et al. A model of wound-healing angiogenesis in soft tissue. Math Biosci. 1996; 136: 35-63.
48. Xue C, Friedman A, Sen CK. A mathematical model of ischemic cutaneous wounds. Proc Natl Acad Sci USA. 2009; 106: 16782-7.
49. Peirce SM, Price RJ, Skalak TC. Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. Am J Physiol Heart Circ Physiol. 2004; 286: H918-25.
50. Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011; 32: 88-111.
51. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003; 161: 1163-77.
52. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation. 2008; 15: 715-38.
53. Mac Gabhann F, Qutub AA, Annex BH, et al. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med. 2010; 2: 694-707.
54. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012; 2: a006502.
55. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 2010; 21: 687-90.
56. Mac Gabhann F, Ji JW, Popel AS. Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol. 2006; 2: e127.
57. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011; 437: 169-83.
58. Mac Gabhann F, Ji JW, Popel AS. Multiscale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann Biomed Eng. 2007; 35: 982-94.
59. Yen P, Finley SD, Engel-Stefanini MO, et al. A two-compartment model of VEGF distribution in the mouse. PLoS ONE. 2011; 6: e27514.
60. Wu FT, Stefanini MO, Mac Gabhann F, et al. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol. 2010; 298: H2174-91.
61. Wu FT, Stefanini MO, Mac Gabhann F, et al. Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Methods Enzymol. 2009; 467: 461-97.
62. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med. 2013; 3: a006569.
63. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141: 52-67.
64. Karagiannis ED, Popel AS. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J Theor Biol. 2006; 238: 124-45.
65. Karagiannis ED, Popel AS. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem. 2004; 279: 39105-14.
66. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem. 2007; 282: 37585-96.
67. Vempati P, Mac Gabhann F, Popel AS. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS ONE. 2010; 5: e11860.
68. Vempati P, Popel AS, Mac Gabhann F. Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol. 2011; 5: 59.
69. Hellstrom M, Phng LK, Gerhardt H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh Migr. 2007; 1: 133-6.
70. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 535-48.
71. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007; 445: 776-80.
72. Guidolin D, Rebuffat P, Albertin G. Celloriented modeling of angiogenesis. Scientific World Journal. 2011; 11: 1735-48.
73. Qutub AA, Mac Gabhann F, Karagiannis ED, et al. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag. 2009; 28: 14-31.
74. Qutub AA, Mac Gabhann F, Karagiannis ED, et al. In silico modeling of angiogenesis at multiple scales: from nanoscale to organ system. In: King MR, Gee DJ, editors. Multiscale modeling of particle interactions: applications in biology and nanotechnology. Hoboken, NJ: Wiley; 2009. pp. 287-320.
75. Jackson T, Zheng X. A cell-based model of endothelial cell migration, proliferation and maturation during corneal angiogenesis. Bull Math Biol. 2010; 72: 830-68.
76. Jakobsson L, Franco CA, Bentley K, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010; 12: 943-53.
77. Bauer AL, Jackson TL, Jiang Y. A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys J. 2007; 92: 3105-21.
78. Bentley K, Gerhardt H, Bates PA. Agentbased simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. J Theor Biol. 2008; 250: 25-36.
79. Chappell JC, Taylor SM, Ferrara N, et al. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell. 2009; 17: 377-86.
80. Kappas NC, Zeng G, Chappell JC, et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol. 2008; 181: 847-58.
81. Hashambhoy YL, Chappell JC, Peirce SM, et al. Computational modeling of interacting VEGF and soluble VEGF receptor concentration gradients. Front Physiol. 2011; 2: 62.
82. Wu FT, Stefanini MO, Mac Gabhann F, et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010; 14: 528-52.
83. Stokes CL, Lauffenburger DA. Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. J Theor Biol. 1991; 152: 377-403.
84. Stokes CL, Lauffenburger DA, Williams SK. Migration of individual microvessel endothelial cells: stochastic model and parameter measurement. J Cell Sci. 1991; 99(Pt 2): 419-30.
85. Milde F, Bergdorf M, Koumoutsakos P. A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J. 2008; 95: 3146-60.
86. Travasso RD, Corvera Poire E, Castro M, et al. Tumor angiogenesis and vascular patterning: a mathematical model. PLoS ONE. 2011; 6: e19989.
87. Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol. 2009; 5: e1000445.
88. Tong S, Yuan F. Dose response of angiogenesis to basic fibroblast growth factor in rat corneal pocket assay: II. Numerical simulations. Microvasc Res. 2008; 75: 16-24.
89. McDougall SR, Watson MG, Devlin AH, et al. A hybrid discrete-continuum mathematical model of pattern prediction in the developing retinal vasculature. Bull Math Biol. 2012; 74: 2272-314.
90. Bauer AL, Jackson TL, Jiang Y, et al. Receptor cross-talk in angiogenesis: mapping environmental cues to cell phenotype using a stochastic, Boolean signaling network model. J Theor Biol. 2010; 264: 838-46.
91. Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003; 21: 1624-36.
92. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004; 5: 261-70.
93. Merks RM, Brodsky SV, Goligorksy MS, et al. Cell elongation is key to in silico replication of in vitro vasculogenesis and subsequent remodeling. Dev Biol. 2006; 289: 44-54.
94. Merks RM, Perryn ED, Shirinifard A, et al. Contact-inhibited chemotaxis in de novo and sprouting blood-vessel growth. PLoS Comput Biol. 2008; 4: e1000163.
95. Qutub AA, Popel AS. Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst Biol. 2009; 3: 13.
96. Pries AR, Reglin B, Secomb TW. Structural adaptation of microvascular networks: functional roles of adaptive responses. Am J Physiol Heart Circ Physiol. 2001; 281: H1015-25.
97. Pries AR, Reglin B, Secomb TW. Structural adaptation of vascular networks: role of the pressure response. Hypertension. 2001; 38: 1476-9.
98. Long BL, Rekhi R, Abrego A, et al. Cells as state machines: cell behavior patterns arise during capillary formation as a function of BDNF and VEGF. J Theor Biol. 2013; 326: 43-57.
99. Long BL, Rekhi R, Abrego A, et al. Cells as state machines: cell behavior patterns arise during capillary formation as a function of BDNF and VEGF. J Theor Biol. 2013; 326: 43-57.
100. Kearney JB, Kappas NC, Ellerstrom C, et al. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood. 2004; 103: 4527-35.
101. Herwig L, Blum Y, Krudewig A, et al. Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo. Curr Biol. 2011; 21: 1942-8.
102. Zeeb M, Strilic B, Lammert E. Resolving cell-cell junctions: lumen formation in blood vessels. Curr Opin Cell Biol. 2010; 22: 626-32.
103. Bentley K, Mariggi G, Gerhardt H, et al. Tipping the balance: robustness of tip cell selection, migration and fusion in angiogenesis. PLoS Comput Biol. 2009; 5: e1000549.
104. Liu G, Qutub AA, Vempati P, et al. Module- based multiscale simulation of angiogenesis in skeletal muscle. Theor Biol Med Model. 2011; 8: 6.
105. Bassingthwaighte JB. Microcirculation and the physiome projects. Microcirculation. 2008; 15: 835-9.
106. Popel AS, Pittman RN. The microcirculation physiome. In: Bronzino JD, Peterson DR, editors. The biomedical engineering handbook, 4th ed. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2013, pp. 13.1-7.
107. Egginton S, Zhou AL, Brown MD, et al. Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res. 2001; 49: 634-46.
108. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn. 2004; 231: 474-88.
109. Clark ER, Clark EL. Microscopic observations on the extra-endothelial cells of living mammalian blood vessels. Am J Anat. 1940; 66: 1-49.
110. Burri PH, Tarek MR. A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec. 1990; 228: 35-45.
111. Gianni-Barrera R, Trani M, Fontanellaz C, et al. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Angiogenesis. 2013; 16: 123-36.
112. Konerding MA, Turhan A, Ravnic DJ, et al. Inflammation-induced intussusceptive angiogenesis in murine colitis. Anat Rec. 2010; 293: 849-57.
113. Szczerba D, Szekely G. Computational model of flow-tissue interactions in intussusceptive angiogenesis. J Theor Biol. 2005; 234: 87-97.
114. Szczerba D, Kurz H, Szekely G. A computational model of intussusceptive microvascular growth and remodeling. J Theor Biol. 2009; 261: 570-83.
115. Lee GS, Filipovic N, Miele LF, et al. Blood flow shapes intravascular pillar geometry in the chick chorioallantoic membrane. J Angiogenes Res. 2010; 2: 11.
116. Sandau K, Kurz H. Modelling of vascular growth processes: a stochastic biophysical approach to embryonic angiogenesis. J Microsc. 1994; 175: 205-13.
117. Levin M, Ewald AJ, McMahon M, et al. A model of intussusceptive angiogenesis. Novartis Found Symp. 2007; 283: 37-42.
118. Ribatti D, Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett. 2012; 316: 126-31.
119. Styp-Rekowska B, Hlushchuk R, Pries AR, et al. Intussusceptive angiogenesis: pillars against the blood flow. Acta Physiol. 2011; 202: 213-23.
120. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol. 2011; 55: 261-8.
121. Gaengel K, Genove G, Armulik A, et al. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 2009; 29: 630-8.
122. Peirce SM, Van Gieson EJ, Skalak TC. Multicellular simulation predicts microvascular patterning and in silico tissue assembly. FASEB J. 2004; 18: 731-3.
123. Arakelyan L, Vainstein V, Agur Z. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis. 2002; 5: 203-14.
124. Evensen L, Micklem DR, Link W, et al. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry A. 2010; 77: 41-51.
125. Aprelikova O, Chandramouli GV, Wood M, et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem. 2004; 92: 491-501.
126. Anderson DE, Hinds MT. Endothelial cell micropatterning: methods, effects, and applications. Ann Biomed Eng. 2011; 39: 2329-45.
127. Stroock AD, Fischbach C. Microfluidic culture models of tumor angiogenesis. Tissue Eng Part A. 2010; 16: 2143-6.
128. Das A, Lauffenburger D, Asada H, et al. A hybrid continuum-discrete modelling approach to predict and control angiogenesis: analysis of combinatorial growth factor and matrix effects on vessel-sprouting morphology. Philos Transact A Math Phys Eng Sci. 2010; 368: 2937-60.
129. Rimchala T, Kamm RD, Lauffenburger DA. Endothelial cell phenotypic behaviors cluster into dynamic state transition programs modulated by angiogenic and angiostatic cytokines. Integr Biol. 2013; 5: 510-22.
130. Staton CA, Reed MW, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol. 2009; 90: 195-221.
131. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc. 2010; 5: 628-35.
132. Evensen L, Link W, Lorens JB. Imagedbased high-throughput screening for antiangiogenic drug discovery. Curr Pharm Des. 2010; 16: 3958-63.
133. Evensen L, Link W, Lorens JB. Imagebased high-throughput screening for inhibitors of angiogenesis. Methods Mol Biol. 2013; 931: 139-51.
134. Shirinifard A, McCollum CW, Bolin MB, et al. 3D quantitative analyses of angiogenic sprout growth dynamics. Dev Dyn. 2013; 242: 518-26.
135. Pollina EA, Legesse-Miller A, Haley EM, et al. Regulating the angiogenic balance in tissues. Cell Cycle. 2008; 7: 2056-70.
136. Olfert IM, Birot O. Importance of antiangiogenic factors in the regulation of skeletal muscle angiogenesis. Microcirculation. 2011; 18: 316-30.
137. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364: 1897-908.
138. Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov. 2010; 9: 17-8.
139. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007; 356: 323-8.
140. Kim KB, Chesney J, Robinson D, et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011; 17: 7451-61.
141. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008; 7: 3598-608.
142. Nabors LB, Fiveash JB, Markert JM, et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol. 2010; 67: 313-9.
143. Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther. 2010; 12: 487-95.
144. Stewart DJ, Kutryk MJB, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN Trial. Mol Ther. 2009; 17: 1109-15.
145. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011; 124: 1765-73.
146. AHA. 2010 clinical trial/clinical science abstracts. Circulation. 2010; 122: 2215.
147. Mac Gabhann F, Annex BH, Popel AS. Gene therapy from the perspective of systems biology. Curr Opin Mol Ther. 2010; 12: 570-7.
148. Anghel A, Taranu G, Seclaman E, et al. Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia. Curr Neurovasc Res. 2011; 8: 183-9.
149. Peterson JE, Zurakowski D, Italiano JE Jr, et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol. 2010; 85: 487-93.
150. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011; 9: 237-49.
151. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008; 8: 1247-55.
152. Ho-Tin-Noe B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res. 2009; 69: 5623-6.
153. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011; 118: 1359-69.
154. Italiano JE Jr, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008; 111: 1227-33.
155. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007; 13: 5341-7.
156. Otrock ZK, Hatoum HA, Awada AH, et al. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol. 2009; 70: 093-102.
157. Park J-W, Chun Y-S, Kim M-S. Hypoxiainducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci. 2004; 94: 221-32.
158. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009; 13: 2780-6.
159. Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1a. Mol Cancer Ther. 2004; 3: 233-44.
160. Dayan F, Monticelli M, Pouyssegur J, et al. Gene regulation in response to graded hypoxia: the non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. J Theor Biol. 2009; 259: 304-16.
161. Qutub AA, Popel AS. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol. 2008; 28: 5106-19.
162. Yu Y, Wang G, Simha R, et al. Pathway switching explains the sharp response characteristic of hypoxia response network. PLoS Comput Biol. 2007; 3: e171.
163. Yucel MA, Kurnaz IA. An in silico model for HIF-a regulation and hypoxia response in tumor cells. Biotechnol Bioeng. 2007; 97: 588-600.
164. Nguyen LK, Cavadas MA, Scholz CC, et al. A dynamic model of the hypoxia-inducible factor 1-alpha (HIF-1alpha) network. J Cell Sci. 2013; 126: 1454-63.
165. Iadevaia S, Lu Y, Morales FC, et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 2010; 70: 6704-14.
166. Hauser K, Abdollahi A, Huber PE. Inverse system perturbations as a new methodology for identifying transcriptomic signaling participants in balanced biological processes. Cell Cycle. 2009; 8: 2718-22.
167. Finley SD, Engel-Stefanini MO, Imoukhuede PI, et al. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol. 2011; 5: 193.
168. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches. PLoS Comput Biol. 2006; 2: e180.
169. Stefanini MO, Wu FT, Mac Gabhann F, et al. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res. 2010; 70: 9886-94.
170. Stoll BR, Migliorini C, Kadambi A, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood. 2003; 102: 2555-61.
171. Finley SD, Popel AS. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Nat Cancer Inst. 2013; 105: 802-11.
172. Segerstrom L, Fuchs D, Backman U, et al. The anti-VEGF antibody bevacizumab potently reduces the growth rate of highrisk neuroblastoma xenografts. Pediatr Res. 2006; 60: 576-81.
173. Willet CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J Clin Oncol. 2005; 23: 8136-9.
174. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-34.
175. Finley SD, Popel AS. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J. 2012; 14: 500-9.
176. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA. 2007; 104: 18363-70.
177. Schugart RC, Friedman A, Zhao R, et al. Wound angiogenesis as a function of tissue oxygen tension: a mathematical model. Proc Natl Acad Sci USA. 2008; 105: 2628-33.
178. Ji JW, Mac Gabhann F, Popel AS. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Am J Physiol Heart Circ Physiol. 2007; 293: H3740-9.
179. Addison-Smith B, McElwain DLS, Maini PK. A simple mechanistic model of sprout spacing in tumour-associated angiogenesis. J Theor Biol. 2008; 250: 1-15.
180. McDougall SR, Anderson ARA, Chaplain MAJ, et al. Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies. Bull Math Biol. 2002; 64: 673-702.
181. Artel A, Mehdizadeh H, Chiu YC, et al. An agent-based model for the investigation of neovascularization within porous scaffolds. Tissue Eng Part A. 2011; 17: 2133-41.
182. Stephanou A, McDougall SR, Anderson ARA, et al. Mathematical modelling of flow in 2D and 3D vascular networks: applications to anti-angiogenic and chemotherapeutic drug strategies. Math Comput Model. 2005; 41: 1137-56.
183. Kuhnert F, Kirshner JR, Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vascular Cell. 2011; 3: 20.
184. Gurney A, Hoey T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vascular Cell. 2011; 3: 18.
185. Liu Z, Turkoz A, Jackson EN, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest. 2011; 121: 800-8.
186. Yan M. Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell. 2011; 3: 17.
187. Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010; 463: E6-7.
188. Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA. 2008; 105: 13775-80.
189. Koskimaki JE, Lee E, Chen W, et al. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis. 2013; 16: 159-70.
190. Koskimaki JE, Rosca EV, Rivera CG, et al. Serpin-derived peptides are anti-angiogenic and suppress breast tumor xenograft growth. Transl Oncol. 2012; 5: 92-7.
191. Rosca EV, Lal B, Koskimaki JE, et al. Collagen IV and CXC chemokine derived anti-angiogenic peptides suppress glioma xenograft growth. Anticancer Drugs. 2012; 23: 706-12.
192. Koskimaki JE, Karagiannis ED, Rosca EV, et al. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia. 2009; 11: 1285-91.
193. Koskimaki JE, Karagiannis ED, Tang BC, et al. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer. 2010; 10: 29.
194. Lee E, Rosca EV, Pandey NB, et al. Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol. 2011; 43: 1812-21.
195. Rosca EV, Koskimaki JE, Rivera CG, et al. Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol. 2011; 12: 1101-16.
196. Rivera CG, Bader JS, Popel AS. Angiogenesis- associated crosstalk between collagens, CXC chemokines, and thrombospondin domain-containing proteins. Ann Biomed Eng. 2011; 39: 2213-22.
197. Rivera CG, Mellberg S, Claesson-Welsh L, et al. Analysis of VEGF-A regulated gene expression in endothelial cells to identify genes linked to angiogenesis. PLoS ONE. 2011; 6: e24887.
198. Chu LH, Rivera CG, Popel AS, et al. Constructing the angiome: a global angiogenesis protein interaction network. Physiol Genomics. 2012; 44: 915-24.
199. Zucker S, Cao J. Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther. 2009; 8: 2371-3.
200. Morrison CJ, Butler GS, Rodriguez D, et al. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009; 21: 645-53.
201. Miller MA, Barkal L, Jeng K, et al. Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr Biol. 2011; 3: 422-38.
202. Chen CH, Miller MA, Sarkar A, et al. Multiplexed protease activity assay for low-volume clinical samples using droplet-based microfluidics and its application to endometriosis. J Am Chem Soc. 2013; 135: 1645-8.
203. Ribba B, Saut O, Colin T, et al. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. J Theor Biol. 2006; 243: 532-41.
204. Dufour A, Sampson NS, Li J, et al. Smallmolecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011; 71: 4977-88.
205. Billy F, Ribba B, Saut O, et al. A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. J Theor Biol. 2009; 260: 545-62.
206. Levine HA, Sleeman BD, Nilsen-Hamilton M. A mathematical model for the roles of pericytes and macrophages in the initiation of angiogenesis. I. The role of protease inhibitors in preventing angiogenesis. Math Biosci. 2000; 168: 77-115.
207. Levine HA, Tucker AL, Nilsen-Hamilton M. A mathematical model for the role of cell signal transduction in the initiation and inhibition of angiogenesis. Growth Factors. 2002; 20: 155-75.
208. Plank MJ, Sleeman BD. A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Math Med Biol. 2003; 20: 135-81.
209. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol. 2010; 28: 237-45.
210. Sun S, Wheeler MF, Obeyeseker M, et al. A deterministic model of growth factorinduced angiogenesis. Bull Math Biol. 2005; 67: 313-37.
211. Edgar LT, Sibole SC, Underwood CJ, et al. A computational model of in vitro angiogenesis based on extracellular matrix fibre orientation. Comput Methods Biomech Biomed Engin. 2013; 16: 790-801.
212. Filipovic N, Tsuda A, Lee GS, et al. Computational flow dynamics in a geometric model of intussusceptive angiogenesis. Microvasc Res. 2009; 78: 286-93.
213. Mitchell TS, Bradley J, Robinson GS, et al. RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis. 2008; 11: 141-51.
214. Lu C, Shahzad MMK, Moreno-Smith M, et al. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010; 9: 176-82.
215. Zheng X, Koh GY, Jackson T. A continuous model of angiogenesis: initiation, extension, and maturation of new blood vessels modulated by vascular endothelial growth factor, angiopoietins, platelet-derived growth factor-B, and pericytes. Disc Cont Dyn Syst Ser B. 2013; 18: 1109-54.
216. Owen MR, Alarcon T, Maini PK, et al. Angiogenesis and vascular remodelling in normal and cancerous tissues. J Math Biol. 2009; 58: 689-721.
217. Plank MJ, Sleeman BD, Jones PF. A mathematical model of tumour angiogenesis, regulated by vascular endothelial growth factor and the angiopoietins. J Theor Biol. 2004; 229: 435-54.
218. Perfahl H, Byrne HM, Chen T, et al. Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS ONE. 2011; 6: e14790.
219. Honstvet CA, Jones PF. Targeting tumour vasculature as a cancer treatment. Comput Math Methods Med. 2007; 8: 1-9.